Connect with people affected by polycythemia vera (PV) or myelofibrosis (MF) through the Incyte Mentor Program or the Ambassadors for Jakafi® (ruxolitinib) program. The Mentor Program offers support for patients and caregivers while the Ambassadors for Jakafi program enables eligible patients taking Jakafi to share their stories of inspiration and hope. Watch the video to find out how to register. Jakafi is a prescription medicine used to treat adults with PV who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is used to treat adults with certain types of MF. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463- 3463. Sponsored by Incyte Corporation. Incyte and the Incyte logo are registered trademarks of Incyte. Jakafi and the Jakafi logo are registered trademarks of Incyte. © 2022, Incyte. MAT-JAK-03839 07/22

Hematologist‐oncologist Gary Grad, MD, explains the results of two clinical studies that explored whether Jakafi® (ruxolitinib) reduced the size of enlarged spleens in adults with intermediate‐2 or highrisk myelofibrosis (MF). Dr. Grad explains what an enlarged spleen is and why it’s important for adults with MF to monitor the size of their spleen on a regular basis. This video is intended for informational use only, and is not designed to replace the medical advice of your Healthcare Professional. Please see your Healthcare Professional if you have further questions. Jakafi® (ruxolitinib) is used to treat adults with intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and polycythemia vera include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‐800‐FDA‐1088. You may also report side effects to Incyte Medical Information at 1‐855‐463‐3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2020, Incyte Corporation. MAT‐JAK‐03743 01/22

Donna was concerned when her flourishing career as a motivational speaker was interrupted by an unexpected decline in her health. After blood tests showed that her platelet count and hematocrit were abnormally high, Donna was diagnosed with a rare, chronic blood cancer called polycythemia vera (PV). Her oncologist prescribed hydroxyurea (HU), but Donna found she could not tolerate it. She was hopeful when her oncologist changed her treatment to Jakafi® (ruxolitinib). Jakafi is a prescription medicine used to treat adults with PV who have already taken a medicine called HU and it did not work well enough or they could not tolerate it. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of myelofibrosis and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2022, Incyte Corporation. MAT-JAK-02969 01/22

Hear from an expert—learn how Jakafi (ruxolitinib) may help reduce the abnormal production of blood cells. Watch this video for a close-up look at how Jakafi works to affect overactive signaling, blood counts, and more. Jakafi® (ruxolitinib) is used to treat adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and polycythemia vera include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi and the Jakafi logo are registered trademarks of Incyte. © 2020, Incyte Corporation. MAT-JAK-03726 01/22

Read below for Selected Safety Information. Hematologist-oncologist Gary Grad, MD explains how a targeted therapy called Jakafi® (ruxolitinib) acts in the body to help treat adults with intermediate- or high-risk myelofibrosis (MF). Jakafi is the first targeted therapy approved by the Food and Drug Administration for the treatment of these patients. Myelofibrosis is a rare, chronic blood cancer that is part of a group of diseases called myeloproliferative neoplasms (MPNs). This video is intended for informational use only, and is not designed to replace the medical advice of your Healthcare Professional. Jakafi used to treat adults with intermediate or high-risk myelofibrosis , including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and polycythemia vera include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2020, Incyte Corporation. MAT-JAK-03731 01/22

Read below for Selected Safety Information. Hematologist-oncologist Gary Grad, MD, addresses the challenges that patients with polycythemia vera (PV) may experience when treated with a chemotherapy medicine called hydroxyurea. He explains that for some adults, hydroxyurea does not control blood counts well enough, while others cannot tolerate the side effects. Dr. Grad explains that PV patients treated with hydroxyurea should track their blood counts, talk with their Healthcare Professional, and ask about a targeted therapy treatment option such as Jakafi® (ruxolitinib). This video is intended for informational use only, and is not designed to replace the medical advice of your Healthcare Professional. Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is also used to treat adults with certain types of myelofibrosis. Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of myelofibrosis and PV include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2020, Incyte Corporation. MAT-JAK-03738 01/22

Read below for Selected Safety Information. A specialist in myeloproliferative neoplasms (MPNs), Gary Grad, MD, discusses 8 risk factors that Healthcare Professionals use to determine the severity of myelofibrosis (MF) in patients. MF and other MPNs are rare, chronic blood cancers. Dr. Grad explains that patients’ Healthcare Professionals can help them understand their MF risk factors and treatment options such as Jakafi® (ruxolitinib). This video is intended for informational use only, and is not designed to replace the medical advice of your Healthcare Professional. Jakafi® (ruxolitinib) is used to treat adults with intermediate or high-risk myelofibrosis (MF). Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and polycythemia vera include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2020, Incyte Corporation. MAT-JAK-03744 01/22

Read below for Selected Safety Information. Hematologist-oncologist Gary Grad, MD, reviews the results of two research studies that explored spleen size and analyzed overall survival in adults with intermediate-2 or high-risk myelofibrosis (MF). Patients were monitored for up to 3 years to determine overall survival. Dr. Grad recommends talking with your Healthcare Professional to help you understand the results of the studies. This video is intended for informational use only, and is not designed to replace the medical advice of your Healthcare Professional. Jakafi® (ruxolitinib) is used to treat adults with intermediate- or high-risk myelofibrosis (MF). Selected Safety Information Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and polycythemia vera include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/. Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte. © 2020, Incyte Corporation. MAT-JAK-03742 01/22